Drug Profile
Fadolmidine - Orion/Societal CDMO
Alternative Names: Fado; MPV 2426; RadolmidineLatest Information Update: 21 Apr 2022
Price :
$50
*
At a glance
- Originator Orion
- Developer Orion; Societal CDMO
- Class Analgesics; Imidazoles; Indans; Small molecules
- Mechanism of Action Alpha 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neuropathic pain; Postoperative pain
Most Recent Events
- 21 Apr 2022 Recro Pharma is now called Societal CDMO
- 14 Apr 2021 No development reported - Phase-II for Postoperative pain (Combination therapy) in USA (Intrathecal)
- 19 Oct 2016 fadolmidine is still in phase I trial for Neuropathic-pain in USA (Topical) (Recro Pharma pipeline, October 2016)